Longwood Fund is a leading healthcare venture capital firm that founds, manages, and builds healthcare companies. The firm partners with entrepreneurs to create, finance, and build healthcare companies that make a meaningful difference in the treatment of disease and improve the lives of patients. Their portfolio companies focus on a variety of healthcare subsectors, including biotechnology, medical devices, and health tech.

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.

Grail

PTC Therapeutics

Pyxis Oncology

Werewolf Therapeutics

ArcherDX

Millendo Therapeutics

Bicycle Therapeutics

Calithera Biosciences

Colorescience

KalVista Pharmaceuticals

TScan Therapeutics

Verastem Oncology

Longwood Fund

Longwood Healthcare Leaders Stanford/San Francisco CEO, January 6-7, 2024 brings together a select group of biopharma leaders, and top biotech and pharma CEOs. https://conta.cc/45B3JsP

Join us January 6-7 for Longwood Healthcare Leaders Stanford/San Francisco CEO to hear from senior-level executives in #biopharma
See more: https://lnkd.in/euXm7nR7

Congratulations to Sitryx on the recent raise, bringing the total to over $75M to develop disease-modifying therapeutics in #autoimmune and #inflammatroy diseases https://lnkd.in/evPXBZug

Important progress for #patients #autism #asd

Read the release here: https://lnkd.in/eeQS_C_W

More than ever, we must evolve how we think and work to increase speed and success in progressing potential therapies from concept to clinic. But what are the key challenges in evolving R&D models and how can we overcome them? At the #LongwoodHealthcareLeaders Fall 2023 Harvard Conference, I participated in a panel focusing on R&D transformation, exploring how we can discover novel therapeutic targets and get them to patients faster. My top takeaways were:
1.      Scaling change and making it stick depends on thinking beyond cost and speed to ensure changes are sustainable and empowering for teams: It takes time and effort to reframe mindsets and behaviors. New models and structures must be designed to accelerate innovation, maximize the skills of our talent in the right place at the right time and enhance cross-collaboration. 
2.      Digital transformation should sit at the core of any R&D strategy: Smart use of AI and human genomics data will increase our speed and probability of success in drug discovery and development and get new therapies to patients faster. At Astellas, we aim to build the best possible relationship between people and digital technology to achieve what has been unattainable until now.
3.      Partnering across the innovation community and with regulators will always be critical to our success: New modalities pose several complex challenges that can’t be navigated alone. We must collaborate across our communities, including industry, academia, and regulators, to break these challenges down and solve them quickly. 
What got us to where we are today won’t be enough to deliver the innovations of tomorrow. By evolving our R&D approach, we can collectively navigate the fast-moving healthcare landscape and transform the lives of patients. #ScienceFirstForPatients #Changingtomorrow

Wonderful learning about innovative commercial models with Moderna Arpa Garay, Akili Labs Eddie Martucci, Ocugen Michael Shine, Ovid Therapeutics Jason Tardio & Klick Brian Fox! #longwoodhealthcareleaders

COM:LONGWOODFUND

Longwood Fund

Analysis Not Available